ASCIA Submissions 2023

• ASCIA letter to the Hon Mark Butler MP, Minister for Health and Ageing, Commonwealth of Australia
  regarding implementation of newborn screening. Submitted 15 August 2023
  
  ASCIA letter to Minister Butler re Newborn Screening 2023-08-15 151.60 KB

• ASCIA lodged a submission in response to the Food Standards Australia New Zealand (FSANZ) call for submissions on Proposal P1028 – Infant Formula.  Submission lodged 13 July 2023.
  
  ASCIA FSANZ P1028 Response July 2023258.66 KB

• ASCIA has lodged two submissions on 23 May 2023 in support of products that are relevant to allergy and immunology, which are on the July 2023 PBAC meeting agenda.

ASCIA letter PBAC Avacopan 2023 05 2366.18 KB

 ASCIA letter PBAC Dupilumab 2023 05 2367.24 KB

• ASCIA letter to the Australian Government Department of Health, to provide information to address the Medical Treatment Overseas Program (MTOP) eligibility criteria for thymic transplant, submitted in May 2023.

• ASCIA has submitted two letters in support of applications for  Medical Research Future Fund (MRFF) research grants, in February and May 2023.

• ASCIA has submitted two joint letters to the federal Health Minister, the Hon Mark Butler MP, with the National Allergy Council and Allergy & Anaphylaxis Australia regarding the feasibility of pricing for PBS listed products -  venom immunotherapy (May 2023) and medical nutrition products for cow’s milk allergy (April 2023).

• ASCIA has lodged four submissions on 20 January 2023 in support of applications for new or updated PBS listings of products that are relevant to allergy and immunology, which are on the March 2023 PBAC meeting agenda, as listed on the ASCIA website www.allergy.org.au/about-ascia/info-updates/pbac-meeting-march-2023
  
  ASCIA letter PBAC ELECARE LCP 2023-01-20117.39 KB
  
  ASCIA letter PBAC EoE JORVEZA 2023-01-2066.86 KB
  
  ASCIA letter PBAC SHINGRIX 2023-01-2067.84 KB
  
  ASCIA letter PBAC SLE ANIFROLUMAB 2023-01-2066.53 KB